Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Safety Study of PBF-1650 in Healthy Volunteers
NCT03798236Phase 1Completed
- Sponsor
- Palobiofarma
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PBF-1650 in psoriasis (5 arms), sponsored by Palobiofarma. Primary endpoint: Number of Adverse events at 7 days. Started Dec 2018; status: completed.
02
Drugs
PBF-1650
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03798236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03798236.